Eckert & Ziegler Q1 Sales Rise 7% Net Income Up

Eckert & Ziegler posted Q1 2026 sales of €72.90 million, up 7% YoY, and net income of €10.40 million, EPS €0.17.
Adjusted EBIT fell 2% due to weaker product mix in the Isotope Products segment, despite overall revenue growth.
Medical segment drove sales increase with higher pharmaceutical radioisotopes, generators, and contract development and manufacturing organization (CDMO) services.
Company reaffirmed FY2026 guidance of around €320 million total sales and approximately €80 million adjusted EBIT, indicating confidence in outlook.